



1644

1FN

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wouters et al.

Serial No.: 09/780,205

Filed: February 9, 2001

For: ANTIBODIES FOR USE IN
TARGETED AND TEMPORARY
TREATMENT OF HUMANS AND
ANIMALS

Confirmation No.: 7934

Examiner: M. Belyavskyi

Group Art Unit: 1644

Attorney Docket No.: 2183-4753US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

December 8, 2006
Date

Betty Vowles
Signature

Betty Vowles
Name (Type/Print)

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the official filing receipt received from the PTO in the referenced application.

The errors to be corrected are as follows:

A foreign application to which this application claims priority has not been included on the filing receipt. It is listed on the Declaration and the "CROSS REFERENCE TO RELATED APPLICATIONS" paragraph. The foreign application is Netherlands Application Serial No. 1009834, filed August 10, 1998.

Serial No.: 09/780,205

Issuance of a corrected filing receipt in accordance with the annotations on the attached filing receipt copy is respectfully requested.

Respectfully submitted,




Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: December 8, 2006
ACT/bv

Enclosure: Copy of Official Filing Receipt with annotations correcting errors
Copy of the Declaration
Copy of Page 1 of the Specification

Document in ProLaw



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

| APPLICATION NUMBER | FILING DATE | GRP ART UNIT | FIL FEE REC'D | ATTY. DOCKET NO. | DRAWINGS | TOT CLAIMS | IND CLAIMS |
|--------------------|-------------|--------------|---------------|------------------|----------|------------|------------|
| 09/780,205 | 02/09/2001 | 1614 | 463 | 4753US | 12 | 32 | 1 |

24247
TRASK BRITT
P.O. BOX 2550
SALT LAKE CITY, UT 84110

RECEIVED

MAR 23 2001

Trask Britt

CONFIRMATION NO. 7934

FILING RECEIPT



OC000000005865453

Date Mailed: 03/15/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Stanislaus Laurens Johan Wouters, Residence Not Provided;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CON OF PCT/NL99/00509 08/10/1999

Foreign Applications

Netherlands Patent Office 1009834 8/10/1998

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Antibodies for use in targeted and temporary treatment of humans and animals

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED


No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



COPY

**Declaration and Power of Attorney Patent Application
(Design or Utility)**

I, the below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: "Antibodies for use in Targeted and Temporary Treatment of Humans and Animals".

the specification of which

- ☐ is attached hereto
☒ was filed on February 9, 2001 as application serial no. 09/780,205 and or PCT International Application number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information know to me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or 35 U.S.C. §365(b) of any foreign application(s) for patent or inventor's certificate, or 35 U.S.C. §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate of PCT International application having a filing date before that of the application on which priority is claimed.

| Prior Foreign Application(s) | | |
|------------------------------|---------------|-------------------------------------|
| Number 1009834 | Country NL | Day/Month/Year Filed 10/08/ 1998 |
| Number | Country | Day/Month/Year Filed |
| Number | Country | Day/Month/Year Filed |



I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

| Prior Provisional Application(s) | |
|----------------------------------|----------------------------|
| Serial Number | Day/Month/Year Filing Date |
| Serial Number | Day/Month/Year Filing Date |
| Serial Number | Day/Month/Year Filing Date |

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s), or under 35 U.S.C. §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

| Prior U.S. or International Application(s) | | |
|--|------------------------------------|--|
| Serial Number PCT/NL99/00509 | Day/Month/Year Filed 08/10/1999 | Status (patented, pending, abandoned) pending |
| Serial Number | Day/Month/Year Filed | Status (patented, pending, abandoned) |
| Serial Number | Day/Month/Year Filed | Status (patented, pending, abandoned) |

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.



Power of Attorney


As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

| Attorney | Registration Number |
|---------------------|---------------------|
| David V. Trask | 22,012 |
| Laurence B. Bond | 30,549 |
| Allen C. Turner | 33,041 |
| Edgar R. Cataxinos | 39,931 |
| Samuel E. Webb | P44,394 |
| William S. Britt | 20,969 |
| Joseph A. Walkowski | 28,765 |
| Kent S. Burningham | 30,453 |
| Brick G. Power | 38,581 |
| Eleanor V. Goodall | 35,162 |
| Thomas J. Rossa | 26,799 |
| James R. Duzan | 28,393 |
| Robert G. Winkle | 37,474 |
| Kenneth C. Booth | 42,342 |

I hereby authorize them or others whom they may appoint to act and rely on instructions from and communicate directly with the person/organization who/which first sends this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instructed otherwise.


Please direct all correspondence in this case to at the address indicated below:

TRASK, BRITT, & ROSSA
P.O. Box 2550
Salt Lake City, Utah 84110
United States of America

| Full Name of Sole or First Inventor | | |
|--|--|---|
| Family Name Wouters | First Given Name Stanislaus | Second Given Name Laurens Johan |
| Residence and Citizenship | | |
| City of Residence Oosterhout | State or Country of Residence the Netherlands | Country of Citizenship the Netherlands |
| Post Office Address | | |
| Street Address Mathildestraat 14 | City Oosterhout | State & Zip Code or Country 4901 HC |
| Signature of Inventor  | | Date 11-5-2001 |

| Full Name of Second Inventor, if any | | |
|--------------------------------------|--|---|
| Family Name Renggli | First Given Name Heinz | Second Given Name Helmut |
| Residence and Citizenship | | |
| City of Residence Malden | State or Country of Residence the Netherlands | Country of Citizenship the Netherlands |
| Post Office Address | | |
| Street Address Droogsestraat 2 | City Malden | State & Zip Code or Country 6581 KH |
| Signature of Inventor | | Date 11-5-2001 |

| Full Name of Third Inventor, if any | | |
|-------------------------------------|--|---|
| Family Name Horbach | First Given Name Danielle | Second Given Name Angelique |
| Residence and Citizenship | | |
| City of Residence Utrecht | State or Country of Residence the Netherlands | Country of Citizenship the Netherlands |
| Post Office Address | | |
| Street Address Bloesemstraat 13 | City Utrecht | State & Zip Code or Country 3581 XA |
| Signature of Inventor | | Date 11-5-2001 |



COPY

ANTIBODIES FOR USE IN TARGETED AND TEMPORARY TREATMENT OF HUMANS AND ANIMALS

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to, and is a continuation of, International Application No. PCT/NL99/00509, filed on August 10, 1999, designating the United States of America, the contents of which are incorporated by this reference, the PCT International Patent Application itself claiming priority from the Netherlands Application Serial No. 1009834, filed August 10, 1998.

The invention relates to antibodies or fragments thereof which can be used for "targeting" of (diagnostically, therapeutically and cosmetically) active substances to desired epitopes. The invention further relates to the use of these antibodies or fragments thereof in the targeted and temporary diagnostic, therapeutic and cosmetic treatment of externally accessible parts of the human and animal body.

The use of an antibody-antigen binding to localize for instance a therapeutically or diagnostically active substance on a determined epitope at a specific site of the body is already known per se. Described for instance in US-5490988 and WO 95/01155 are antibodies and fragments of antibodies to which a therapeutically active substance is coupled for the "targeting" of antimicrobial substances to epitopes of pathogenic compounds in the oral cavity. In EP 0736544 are described antibodies which recognize specific protein structures on the tooth, whereby therapeutic or cosmetic substances can be applied specifically and locally to the tooth. Targeted and local administering of active substances achieves maximum effectiveness of these substances.

Through conjugation with a dye (for instance erythrocine) such antibodies or fragments thereof can be used for the detection of for instance dental plaque. Early detection of plaque provides the possibility of removing the plaque before it causes infectious or carious disorders of the teeth and/or surrounding tissues. By bringing the teeth and surrounding tissues into contact with the antibody coupled to a dye which detects the plaque, the plaque can be made visible and then be removed by cleaning the teeth and the surrounding tissues, in particular at those locations where the presence of plaque has been determined.